Relief Therapeutics Holding AG (RLF.SW)
CHF 4.1
(-6.82%)
CHF 4.1
(-6.82%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 6.03 Million CHF | -0.79% |
| 2022 | 6.08 Million CHF | 83.11% |
| 2021 | 3.32 Million CHF | 0.0% |
| 2020 | - CHF | 0.0% |
| 2019 | - CHF | -100.0% |
| 2018 | 567 Thousand CHF | 0.0% |
| 2017 | - CHF | -100.0% |
| 2016 | 15 Thousand CHF | -94.14% |
| 2015 | 256.11 Thousand CHF | -98.69% |
| 2014 | 19.49 Million CHF | -5.91% |
| 2013 | 20.71 Million CHF | 0.0% |
| 2012 | - CHF | 0.0% |
| 2011 | - CHF | -100.0% |
| 2010 | 386.38 Thousand CHF | -97.19% |
| 2009 | 13.74 Million CHF | -5.53% |
| 2008 | 14.54 Million CHF | -1.9% |
| 2007 | 14.82 Million CHF | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 5.58 Million CHF | 0.0% |
| 2023 Q2 | 3.02 Million CHF | 0.0% |
| 2023 FY | 6.03 Million CHF | -0.79% |
| 2023 Q4 | 3.01 Million CHF | 0.0% |
| 2022 FY | 6.08 Million CHF | 83.11% |
| 2022 Q2 | 3.24 Million CHF | 0.0% |
| 2022 Q4 | 2.83 Million CHF | 0.0% |
| 2021 Q2 | - CHF | 0.0% |
| 2021 Q4 | 3.32 Million CHF | 0.0% |
| 2021 FY | 3.32 Million CHF | 0.0% |
| 2020 Q2 | - CHF | 0.0% |
| 2020 FY | - CHF | 0.0% |
| 2020 Q4 | - CHF | 0.0% |
| 2019 Q2 | - CHF | 0.0% |
| 2019 FY | - CHF | -100.0% |
| 2019 Q4 | - CHF | 0.0% |
| 2018 Q2 | - CHF | 0.0% |
| 2018 Q4 | 567 Thousand CHF | 0.0% |
| 2018 FY | 567 Thousand CHF | 0.0% |
| 2017 FY | - CHF | -100.0% |
| 2017 Q4 | - CHF | 0.0% |
| 2017 Q2 | - CHF | 0.0% |
| 2016 Q1 | 3750.00 CHF | 0.0% |
| 2016 FY | 15 Thousand CHF | -94.14% |
| 2016 Q2 | 3750.00 CHF | 0.0% |
| 2016 Q4 | 15 Thousand CHF | 0.0% |
| 2015 Q3 | 64.02 Thousand CHF | 0.0% |
| 2015 FY | 256.11 Thousand CHF | -98.69% |
| 2015 Q1 | 64.02 Thousand CHF | 0.0% |
| 2015 Q4 | 3750.00 CHF | -94.14% |
| 2015 Q2 | 64.02 Thousand CHF | 0.0% |
| 2014 Q4 | 64.02 Thousand CHF | -98.69% |
| 2014 FY | 19.49 Million CHF | -5.91% |
| 2014 Q3 | 4.87 Million CHF | 0.0% |
| 2014 Q2 | 4.87 Million CHF | 0.0% |
| 2014 Q1 | 4.87 Million CHF | 0.0% |
| 2013 Q4 | 4.87 Million CHF | -5.91% |
| 2013 Q3 | 5.17 Million CHF | 0.0% |
| 2013 Q2 | 5.17 Million CHF | 0.0% |
| 2013 Q1 | 5.17 Million CHF | 0.0% |
| 2013 FY | 20.71 Million CHF | 0.0% |
| 2012 FY | - CHF | 0.0% |
| 2012 Q4 | 5.17 Million CHF | 0.0% |
| 2012 Q2 | - CHF | 0.0% |
| 2012 Q1 | - CHF | 0.0% |
| 2012 Q3 | - CHF | 0.0% |
| 2011 Q2 | - CHF | 0.0% |
| 2011 Q4 | - CHF | 0.0% |
| 2011 FY | - CHF | -100.0% |
| 2011 Q3 | - CHF | 0.0% |
| 2011 Q1 | - CHF | 0.0% |
| 2010 Q1 | 96.59 Thousand CHF | 0.0% |
| 2010 Q4 | - CHF | -100.0% |
| 2010 Q3 | 96.59 Thousand CHF | 0.0% |
| 2010 Q2 | 96.59 Thousand CHF | 0.0% |
| 2010 FY | 386.38 Thousand CHF | -97.19% |
| 2009 Q2 | 3.43 Million CHF | 0.0% |
| 2009 Q3 | 3.43 Million CHF | 0.0% |
| 2009 Q4 | 96.59 Thousand CHF | -97.19% |
| 2009 FY | 13.74 Million CHF | -5.53% |
| 2009 Q1 | 3.43 Million CHF | 0.0% |
| 2008 Q4 | 3.43 Million CHF | -5.53% |
| 2008 Q2 | 3.63 Million CHF | 0.0% |
| 2008 Q1 | 3.63 Million CHF | 0.0% |
| 2008 FY | 14.54 Million CHF | -1.9% |
| 2008 Q3 | 3.63 Million CHF | 0.0% |
| 2007 FY | 14.82 Million CHF | 0.0% |
| 2007 Q3 | 3.7 Million CHF | 0.0% |
| 2007 Q2 | 3.7 Million CHF | 0.0% |
| 2007 Q1 | 3.7 Million CHF | 0.0% |
| 2007 Q4 | 3.63 Million CHF | -1.9% |
| 2006 Q4 | 3.7 Million CHF | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Addex Therapeutics Ltd | 1.61 Million CHF | -273.055% |
| BB Biotech AG | -199.56 Million CHF | 103.023% |
| Basilea Pharmaceutica AG | 157.63 Million CHF | 96.173% |
| Evolva Holding SA | 9.43 Million CHF | 36.076% |
| Idorsia Ltd | 152.38 Million CHF | 96.041% |
| Kuros Biosciences AG | 33.56 Million CHF | 82.025% |
| Molecular Partners AG | 7.03 Million CHF | 14.28% |
| Santhera Pharmaceuticals Holding AG | 103.41 Million CHF | 94.166% |